Health
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate – BioSpace
Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19…
Sanofi and GSK initiateglobal Phase 3clinical efficacy study of COVID-19 vaccinecandidate
- Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants
- A booster study program will begin in the coming weeks to complement Phase 3 trial
- Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
PARIS and LONDON May 27, 2021 Today, Sanofi and GSK started enrollment…
Continue Reading
-
Noosa News20 hours agoPilot left with life-threatening burns to his body as plane crashes to ground in Raglan, Queensland
-
Noosa News14 hours agoTeenage girl killed in house fire in Lawnton, Queensland as police probe potential e-bike link
-
Noosa News24 hours agoBrisbane Lions beat Carlton by 35 points to set up third straight AFLW grand final against Kangaroos
-
Noosa News22 hours agoWhen will my HECS debt be cut? Millions of Australians wake to 20 per cent cut